Your browser is no longer supported. Please, upgrade your browser.
Settings
ONCR [NASD]
Oncorus, Inc.
Index- P/E- EPS (ttm)-2.66 Insider Own0.30% Shs Outstand25.68M Perf Week-1.76%
Market Cap252.94M Forward P/E- EPS next Y-2.85 Insider Trans-46.86% Shs Float25.13M Perf Month-10.66%
Income-62.40M PEG- EPS next Q-0.64 Inst Own79.30% Short Float2.81% Perf Quarter-39.29%
Sales- P/S- EPS this Y-62.40% Inst Trans2.05% Short Ratio5.92 Perf Half Y-24.24%
Book/sh6.33 P/B1.50 EPS next Y-15.40% ROA-36.40% Target Price- Perf Year-
Cash/sh5.99 P/C1.58 EPS next 5Y- ROE-70.20% 52W Range9.01 - 37.86 Perf YTD-70.71%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-74.99% Beta-
Dividend %- Quick Ratio15.10 Sales past 5Y- Gross Margin- 52W Low5.11% ATR0.52
Employees56 Current Ratio15.10 Sales Q/Q- Oper. Margin- RSI (14)34.66 Volatility5.96% 5.14%
OptionableYes Debt/Eq0.00 EPS Q/Q41.90% Profit Margin- Rel Volume0.42 Prev Close9.57
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume119.35K Price9.47
Recom1.70 SMA20-5.31% SMA50-16.15% SMA200-44.87% Volume50,580 Change-1.04%
Mar-16-21Initiated Maxim Group Buy $35
Oct-27-20Initiated Piper Sandler Overweight $40
Oct-27-20Initiated Jefferies Buy $22
Oct-27-20Initiated Evercore ISI Outperform $35
Sep-22-21 10:15AM  
Aug-04-21 07:00AM  
Jul-29-21 07:00AM  
Jul-01-21 05:16AM  
Jun-17-21 07:00AM  
Jun-15-21 07:57AM  
May-27-21 07:05AM  
May-26-21 07:00AM  
May-04-21 07:00AM  
Apr-02-21 05:04AM  
Mar-10-21 07:00AM  
Feb-12-21 09:31AM  
Feb-11-21 10:15PM  
Feb-09-21 05:01PM  
Jan-20-21 07:00AM  
Jan-04-21 07:00AM  
Jan-02-21 03:59AM  
Dec-14-20 08:00AM  
Dec-07-20 08:00AM  
Nov-24-20 08:00AM  
Nov-12-20 07:00AM  
Nov-11-20 07:00AM  
Oct-05-20 04:05PM  
Oct-02-20 11:23AM  
Oct-01-20 07:12PM  
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Queva ChristopheCSO and SVP, ResearchJun 02Sale16.6610,656177,52947,626Jun 03 05:15 PM
Queva ChristopheCSO and SVP, ResearchJun 01Sale16.6912,899215,28458,282Jun 03 05:15 PM
Queva ChristopheCSO and SVP, ResearchMay 24Option Exercise1.8135,56164,36571,181May 26 04:31 PM
Queva ChristopheCSO and SVP, ResearchApr 30Sale15.9723,555376,12335,620May 04 05:33 PM
Queva ChristopheCSO and SVP, ResearchApr 28Sale15.2217,990273,80859,175Apr 28 07:32 PM
Queva ChristopheCSO and SVP, ResearchApr 27Sale15.002113,16577,165Apr 28 07:32 PM
Queva ChristopheCSO and SVP, ResearchApr 26Sale15.005481077,376Apr 28 07:32 PM
Ashburn TheodorePresident and CEOApr 07Option Exercise5.324,69924,99923,145Apr 09 04:30 PM
Queva ChristopheCSO and SVP, ResearchApr 06Sale15.015,30079,55377,430Apr 08 04:57 PM
Flynn James EDirectorFeb 17Buy19.00300,0005,700,0001,401,905Feb 18 06:44 PM
Ashburn TheodorePresident and CEODec 31Option Exercise1.811,9003,43918,446Apr 09 04:30 PM
Flynn James EDirectorOct 06Buy15.001,000,00015,000,0001,268,344Oct 08 05:31 PM
MPM SunStates Fund, L.P.10% OwnerOct 06Buy15.00173,7762,606,6402,849,453Oct 08 06:35 PM
MPM BioVentures 2014, L.P.10% OwnerOct 06Buy15.00173,7762,606,6402,849,453Oct 08 06:31 PM
GADICKE ANSBERT10% OwnerOct 06Buy15.00325,0004,875,0002,849,453Oct 08 06:28 PM
EVNIN LUKEDirectorOct 06Buy15.00151,2252,268,3752,492,843Oct 08 06:27 PM
UBS Oncology Impact Fund L.P.10% OwnerOct 06Buy15.00151,2242,268,3602,377,025Oct 08 06:26 PM